SBIO holdings
ALPS Medical Breakthroughs ETF
Positions
89 stored of 89 reported, largest first by weight
| # | Holding | ISIN | CUSIP | Weight | Value (USD) | Type | Issuer type | Country | Currency |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Alkermes Plc | IE00B56GVS15 | G01767105 | 4.478% | $7.2M | Equity (common) | Corporate | Ireland | USD |
| 2 | Kymera Therapeutics Inc | US5015751044 | 501575104 | 4.235% | $6.9M | Equity (common) | Corporate | United States | USD |
| 3 | Celcuity Inc | US15102K1007 | 15102K100 | 3.917% | $6.3M | Equity (common) | Corporate | United States | USD |
| 4 | Mirum Pharmaceuticals Inc | US6047491013 | 604749101 | 3.902% | $6.3M | Equity (common) | Corporate | United States | USD |
| 5 | Spyre Therapeutics Inc | US00773J2024 | 00773J202 | 3.678% | $6.0M | Equity (common) | Corporate | United States | USD |
| 6 | Cg Oncology Inc | US1569441009 | 156944100 | 3.351% | $5.4M | Equity (common) | Corporate | United States | USD |
| 7 | Apogee Therapeutics Inc | US03770N1019 | 03770N101 | 2.930% | $4.7M | Equity (common) | Corporate | United States | USD |
| 8 | Xenon Pharmaceuticals Inc | CA98420N1050 | 98420N105 | 2.901% | $4.7M | Equity (common) | Corporate | Canada | USD |
| 9 | Travere Therapeutics Inc | US89422G1076 | 89422G107 | 2.772% | $4.5M | Equity (common) | Corporate | United States | USD |
| 10 | Dianthus Therapeutics Inc | US2528281080 | 252828108 | 2.635% | $4.3M | Equity (common) | Corporate | United States | USD |
| 11 | Newamsterdam Pharma Co Nv | NL00150012L7 | N62509109 | 2.467% | $4.0M | Equity (common) | Corporate | Netherlands | USD |
| 12 | Viking Therapeutics Inc | US92686J1060 | 92686J106 | 2.410% | $3.9M | Equity (common) | Corporate | United States | USD |
| 13 | Crinetics Pharmaceuticals Inc | US22663K1079 | 22663K107 | 2.371% | $3.8M | Equity (common) | Corporate | United States | USD |
| 14 | Acadia Pharmaceuticals Inc | US0042251084 | 004225108 | 2.353% | $3.8M | Equity (common) | Corporate | United States | USD |
| 15 | Edgewise Therapeutics Inc | US28036F1057 | 28036F105 | 2.335% | $3.8M | Equity (common) | Corporate | United States | USD |
| 16 | Denali Therapeutics Inc | US24823R1059 | 24823R105 | 2.126% | $3.4M | Equity (common) | Corporate | United States | USD |
| 17 | Oruka Therapeutics Inc | US6876041087 | 687604108 | 1.805% | $2.9M | Equity (common) | Corporate | United States | USD |
| 18 | Structure Therapeutics Inc | US86366E1064 | 86366E106 | 1.775% | $2.9M | Equity (common) | Corporate | Cayman Islands | USD |
| 19 | Disc Medicine Inc | US2546041011 | 254604101 | 1.691% | $2.7M | Equity (common) | Corporate | United States | USD |
| 20 | Ideaya Biosciences Inc | US45166A1025 | 45166A102 | 1.649% | $2.7M | Equity (common) | Corporate | United States | USD |
| 21 | Vera Therapeutics Inc | US92337R1014 | 92337R101 | 1.615% | $2.6M | Equity (common) | Corporate | United States | USD |
| 22 | Tarsus Pharmaceuticals Inc | US87650L1035 | 87650L103 | 1.611% | $2.6M | Equity (common) | Corporate | United States | USD |
| 23 | Relay Therapeutics Inc | US75943R1023 | 75943R102 | 1.600% | $2.6M | Equity (common) | Corporate | United States | USD |
| 24 | Mineralys Therapeutics Inc | US6031701013 | 603170101 | 1.588% | $2.6M | Equity (common) | Corporate | United States | USD |
| 25 | Celldex Therapeutics Inc | US15117B2025 | 15117B202 | 1.333% | $2.2M | Equity (common) | Corporate | United States | USD |
| 26 | Zai Lab Ltd | US98887Q1040 | 98887Q104 | 1.258% | $2.0M | Equity (common) | Corporate | Cayman Islands | USD |
| 27 | Pharvaris Nv | NL00150005Y4 | N69605108 | 1.231% | $2.0M | Equity (common) | Corporate | Netherlands | USD |
| 28 | Sionna Therapeutics Inc | US8294011080 | 829401108 | 1.227% | $2.0M | Equity (common) | Corporate | United States | USD |
| 29 | Rapport Therapeutics Inc | US75383L1026 | 75383L102 | 1.203% | $1.9M | Equity (common) | Corporate | United States | USD |
| 30 | Sarepta Therapeutics Inc | US8036071004 | 803607100 | 1.195% | $1.9M | Equity (common) | Corporate | United States | USD |
| 31 | Lakefront Biotherapeutics Nv | US36315X1019 | 36315X101 | 1.191% | $1.9M | Equity (common) | Corporate | Belgium | USD |
| 32 | Tyra Biosciences Inc | US90240B1061 | 90240B106 | 1.146% | $1.9M | Equity (common) | Corporate | United States | USD |
| 33 | Novavax Inc | US6700024010 | 670002401 | 1.139% | $1.8M | Equity (common) | Corporate | United States | USD |
| 34 | Stoke Therapeutics Inc | US86150R1077 | 86150R107 | 1.125% | $1.8M | Equity (common) | Corporate | United States | USD |
| 35 | Agios Pharmaceuticals Inc | US00847X1046 | 00847X104 | 1.097% | $1.8M | Equity (common) | Corporate | United States | USD |
| 36 | Vericel Corp | US92346J1088 | 92346J108 | 1.078% | $1.7M | Equity (common) | Corporate | United States | USD |
| 37 | Nuvation Bio Inc | US67080N1019 | 67080N101 | 1.055% | $1.7M | Equity (common) | Corporate | United States | USD |
| 38 | Palvella Therapeutics Inc | US6979471090 | 697947109 | 1.032% | $1.7M | Equity (common) | Corporate | United States | USD |
| 39 | Taysha Gene Therapies Inc | US8776191061 | 877619106 | 1.024% | $1.7M | Equity (common) | Corporate | United States | USD |
| 40 | Amylyx Pharmaceuticals Inc | US03237H1014 | 03237H101 | 1.011% | $1.6M | Equity (common) | Corporate | United States | USD |
| 41 | Immatics Nv | NL0015285941 | N44445109 | 0.983% | $1.6M | Equity (common) | Corporate | Netherlands | USD |
| 42 | Immunocore Holdings Plc | US45258D1054 | 45258D105 | 0.933% | $1.5M | Equity (common) | Corporate | United Kingdom | USD |
| 43 | Mbx Biosciences Inc | US55287L1017 | 55287L101 | 0.900% | $1.5M | Equity (common) | Corporate | United States | USD |
| 44 | Bicara Therapeutics Inc | US0554771032 | 055477103 | 0.878% | $1.4M | Equity (common) | Corporate | United States | USD |
| 45 | Moonlake Immunotherapeutics | KY61559X1045 | 61559X104 | 0.876% | $1.4M | Equity (common) | Corporate | Cayman Islands | USD |
| 46 | Kalvista Pharmaceuticals Inc | US4834971032 | 483497103 | 0.865% | $1.4M | Equity (common) | Corporate | United States | USD |
| 47 | Arrivent Biopharma Inc | US04272N1028 | 04272N102 | 0.852% | $1.4M | Equity (common) | Corporate | United States | USD |
| 48 | Oculis Holding Ag | CH1242303498 | H5870P102 | 0.837% | $1.4M | Equity (common) | Corporate | Switzerland | USD |
| 49 | Maze Therapeutics Inc | US5787841007 | 578784100 | 0.811% | $1.3M | Equity (common) | Corporate | United States | USD |
| 50 | Mannkind Corp | US56400P7069 | 56400P706 | 0.740% | $1.2M | Equity (common) | Corporate | United States | USD |
| 51 | Corvus Pharmaceuticals Inc | US2210151005 | 221015100 | 0.662% | $1.1M | Equity (common) | Corporate | United States | USD |
| 52 | Olema Pharmaceuticals Inc | US68062P1066 | 68062P106 | 0.661% | $1.1M | Equity (common) | Corporate | United States | USD |
| 53 | Zenas Biopharma Inc | US98937L1052 | 98937L105 | 0.629% | $1.0M | Equity (common) | Corporate | United States | USD |
| 54 | Kura Oncology Inc | US50127T1097 | 50127T109 | 0.574% | $929K | Equity (common) | Corporate | United States | USD |
| 55 | Ars Pharmaceuticals Inc | US82835W1080 | 82835W108 | 0.574% | $928K | Equity (common) | Corporate | United States | USD |
| 56 | Xencor Inc | US98401F1057 | 98401F105 | 0.555% | $898K | Equity (common) | Corporate | United States | USD |
| 57 | Theravance Biopharma Inc | KYG8807B1068 | G8807B106 | 0.518% | $839K | Equity (common) | Corporate | Cayman Islands | USD |
| 58 | Geron Corp | US3741631036 | 374163103 | 0.510% | $825K | Equity (common) | Corporate | United States | USD |
| 59 | Design Therapeutics Inc | US25056L1035 | 25056L103 | 0.412% | $666K | Equity (common) | Corporate | United States | USD |
| 60 | Alto Neuroscience Inc | US02157Q1094 | 02157Q109 | 0.397% | $643K | Equity (common) | Corporate | United States | USD |
| 61 | Candel Therapeutics Inc | US1374041093 | 137404109 | 0.387% | $627K | Equity (common) | Corporate | United States | USD |
| 62 | Tectonic Therapeutic Inc | US8789721086 | 878972108 | 0.373% | $603K | Equity (common) | Corporate | United States | USD |
| 63 | Fulgent Genetics Inc | US3596641098 | 359664109 | 0.361% | $584K | Equity (common) | Corporate | United States | USD |
| 64 | Rigel Pharmaceuticals Inc | US7665597024 | 766559702 | 0.359% | $581K | Equity (common) | Corporate | United States | USD |
| 65 | Aclaris Therapeutics Inc | US00461U1051 | 00461U105 | 0.350% | $566K | Equity (common) | Corporate | United States | USD |
| 66 | Upstream Bio Inc | US91678A1079 | 91678A107 | 0.288% | $466K | Equity (common) | Corporate | United States | USD |
| 67 | Neurogene Inc | US64135M1053 | 64135M105 | 0.280% | $453K | Equity (common) | Corporate | United States | USD |
| 68 | Compass Therapeutics Inc | US20454B1044 | 20454B104 | 0.273% | $442K | Equity (common) | Corporate | United States | USD |
| 69 | Altimmune Inc | US02155H2004 | 02155H200 | 0.253% | $409K | Equity (common) | Corporate | United States | USD |
| 70 | Vanda Pharmaceuticals Inc | US9216591084 | 921659108 | 0.243% | $393K | Equity (common) | Corporate | United States | USD |
| 71 | Delcath Systems Inc | US24661P8077 | 24661P807 | 0.239% | $386K | Equity (common) | Corporate | United States | USD |
| 72 | Atea Pharmaceuticals Inc | US04683R1068 | 04683R106 | 0.237% | $384K | Equity (common) | Corporate | United States | USD |
| 73 | Zura Bio Ltd | KYG9TY5A1016 | G9TY5A101 | 0.236% | $382K | Equity (common) | Corporate | Cayman Islands | USD |
| 74 | Regenxbio Inc | US75901B1070 | 75901B107 | 0.231% | $373K | Equity (common) | Corporate | United States | USD |
| 75 | Rezolute Inc | US76200L3096 | 76200L309 | 0.201% | $326K | Equity (common) | Corporate | United States | USD |
| 76 | Anavex Life Sciences Corp | US0327973006 | 032797300 | 0.179% | $289K | Equity (common) | Corporate | United States | USD |
| 77 | Akebia Therapeutics Inc | US00972D1054 | 00972D105 | 0.174% | $282K | Equity (common) | Corporate | United States | USD |
| 78 | Protara Therapeutics Inc | US74365U1079 | 74365U107 | 0.160% | $259K | Equity (common) | Corporate | United States | USD |
| 79 | Forte Biosciences Inc | US34962G2084 | 34962G208 | 0.152% | $246K | Equity (common) | Corporate | United States | USD |
| 80 | Bicycle Therapeutics Plc | US0887861088 | 088786108 | 0.149% | $241K | Equity (common) | Corporate | United Kingdom | USD |
| 81 | Arcturus Therapeutics Holdings Inc | US03969T1097 | 03969T109 | 0.143% | $232K | Equity (common) | Corporate | United States | USD |
| 82 | Aardvark Therapeutics Inc | US0029421007 | 002942100 | 0.057% | $92K | Equity (common) | Corporate | United States | USD |
| 83 | State Street Institutional Treasury Plus Money Market Fund | US8574928623 | 857492862 | 0.004% | $7K | Short-term investment vehicles (cash funds) | Registered fund | United States | USD |
| 84 | Astrazeneca Plc | Not reported | Not reported | 0.000% | $0 | Equity derivatives | Corporate | United States | USD |
| 85 | Chinook Therapeutics Inc | Not reported | Not reported | 0.000% | $0 | Equity derivatives | Corporate | United States | USD |
| 86 | Omniab Inc | US68218J3014 | 68218J301 | 0.000% | $0 | Equity derivatives | Corporate | United States | USD |
| 87 | Novo Nordisk A/s | Not reported | Not reported | 0.000% | $0 | Equity derivatives | Corporate | Denmark | USD |
| 88 | Omniab Inc | US68218J2024 | 68218J202 | 0.000% | $0 | Equity derivatives | Corporate | United States | USD |
| 89 | SECURITIES LENDING - GENERAL | Not reported | Not reported | 0.000% | $0 | Short-term investment vehicles (cash funds) | Registered fund | United States | USD |